BEGIN:VCALENDAR
PRODID:-//Microsoft Corporation//Outlook MIMEDIR//EN
VERSION:1.0
BEGIN:VEVENT
DTSTART:20131120T172000Z
DTEND:20131120T180000Z
LOCATION:Booth 3947
DESCRIPTION;ENCODING=QUOTED-PRINTABLE:ABSTRACT: New experimental modalities incorporating technological advances in miniaturization, parallelization, and especially robotics have opened up new ways to study biological systems in their normal and diseased states and has catalyzed transformational changes in how we study disease and search for cures. The knowledge gained will enable the development of predictive models that dramatically increase the specificity and timeliness of diagnosis for a wide range of common diseases. These quantitative, data-based models could also guide the search for new therapies by delivering accurate predictions about the efficacy of treatment options, thus realizing the era of personalized medicine. Because of the enormous scale of the data in this new era of ubiquitous sequencing/imaging and concomitant developments of other data- intensive 'omics and imaging technologies, the computational challenge of making sense of massive, heterogeneous data sets to guide our R&D programs throughout Janssen Pharma is formidable indeed. Our goal at Janssen is to develop and deploy state-of-the-art Informatics capabilities and computational expertise in high-performance computing in order to extract information and knowledge from these "big data" sets. This focus is guiding our ongoing efforts, illustrated by a few examples, to support researchers throughout our R&D enterprise in helping them bring products to market  as the patients are waiting!
SUMMARY:High-Performance Computing in Pharmaceutical R&D - Transforming Data Into Therapies
PRIORITY:3
END:VEVENT
END:VCALENDAR